GlassScriptPhysician profile
David M Colon
NPI 1447406079
$5,265.19
in general payments reported to CMS, 2019-2025
45 companies · $1,045 in 2025
The $1,045 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,409 · 2020: $285 · 2021: $356 · 2022: $475 · 2023: $856 · 2024: $838 · 2025: $1,045.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,739.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,739.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $578.04 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $555.36 | 2019-2025 | Qulipta, Ubrelvy, Linzess |
| Novo Nordisk INC | $534.76 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $471.39 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $393.59 | 2019-2025 | |
| Glaxosmithkline, LLC. | $289.54 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Lilly USA, LLC | $271.40 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $227.06 | 2019-2024 | Xarelto, Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $206.72 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Merck Sharp & Dohme LLC | $142.59 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $139.78 | 2019-2025 | Xifaxan, Trulance |
| Amneal Pharmaceuticals LLC | $108.93 | 2019-2025 | Unithroid |
| Sanofi-Aventis U.S. LLC | $93.98 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $91.21 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $90.31 | 2019-2024 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Colon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.